Identification and characterization of TspA, a major CD4+ T-cell- and B-cell-stimulating Neisseria-specific antigen

Infection and Immunity

Volumn 67, Issue 7, 1999, Pages 3533-3541

  Kizil, Goksel ^a   Todd, Ian ^a   Atta, Mustafa ^a   Borriello, S Peter ^b   Ait Tahar, Kamel ^a   Ala'aldeen, Dlawer A A ^a,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CD4 ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; DNA SEQUENCE; HUMAN; HUMAN CELL; IMMUNOGENICITY; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SEQUENCE ANALYSIS; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 0033042694     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.7.3533-3541.1999     Document Type: Article

References (31)

1. Abou-Zeid, C., E. Filley, J. Steele, and R. Gav. 1987. A simple new method for using antigens separated by polyacrylamide gel electrophoresis to stimulate lymphocytes in vitro after converting bands cut from Western blots into antigen-bearing particles. J. Immunol. Methods 98:5-10.
2. Adhikari, P., S. A. Berish, A. J. Nowalk, K. L. Veraldi, S. A. Morse, and T. A. Mietzner. 1996. The fbpABC locus of Neisseria gonorrhoea functions in the periplasm-to-cytosol transport of iron. J. Bacteriol. 178:2145-2149.
3. Ala'Aldeen, D. A., H. A. Davies, R. A. Wall, and S. P. Borriello. 1990. The 70 kilodalton iron regulated protein of Neisseria meningitidis is not the human transferrin receptor. FEMS Microbiol. Lett. 69:37-42.
4. Ala'Aldeen, D. A. A. 1996. Transferrin receptors of Neisseria meningitidis: promising candidates for a broadly cross-protective vaccine. J. Med. Microbiol. 44:237-243.
5. Ala'Aldeen, D. A. A. 1997. Neisseria meningitidis, p. 277-304. In A. M. Emmerson, P. Hawkey, and S. Gilaspy (ed.) Principles and practice of clinical bacteriology. John Wiley and Sons, Chichester, United Kingdom.
6. Ala'Aldeen, D. A. A., P. Stevenson, E. Griffiths, A. R. Gorringe, L. I. Irons, A. Robinson, S. Hyde, and S. P. Borriello. 1994. Immune responses in man and animals to meningococcal transferrin-binding proteins: implications for vaccine design. Infect. Immun. 62:2894-2900.
7. Ala'Aldeen, D. A. A., A. H. Westphal, A. de Kok, V. Weston, M. Atta, T. J. Baldwin, J. Bartley, and S. P. Borriello. 1996. Cloning, sequencing, characterisation and implications on vaccine design of the novel dihydrolipoyl acetyltransferase of Neisseria meningitidis. J. Med. Microbiol. 45:419-432.
8. Bjune, G., E. A. Hoiby, J. K. Gronnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nokleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Froholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
9. Danve, B., L. Lissolo, M. Mignon, P. Dumas, S. Colombani, A. B. Schryvers, and M.-J. Quentin-Millet. 1993. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine 11:1214-1220.
10. Delvig, A. A., E. Rosenqvist, F. Oftung, and J. H. Robinson. 1997. T-cell epitope mapping the porB protein of serogroup B Neisseria meningitidis in B 10 congenic strains of mice. Clin. Immunol. Immunopathol. 85:134-142.
11. De Moraes, J. C., B. A. Perkins, M. C. Camargo, N. T. P. Hidalgo, H. A. Barbosa, C. T. Sacchi, I. M. L. Gral, V. L. Gattas, H. G. Vasconcelos, B. D. Plikaytis, J. D. Wenter, and C. V. Broome. 1992. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340:1074-1078.
12. Davenport, C., G. F. Bottazzo, and I. Todd. 1992. Stimulation of human B cells specific for candida albicans for monoclonal antibody production. FEMS Microbiol. Immunol. 89:335-344.
13. Frasch, C. E. 1983. Immunisation against Neisseria meningitidis, p. 115-144. In C. Easmon and J. Jeljaszewics (ed.), Medical microbiology. Academic Press, London, United Kingdom.
14. Kruisbeek, A. M., and D. Amsen. 1996. Mechanisms underlying T-cell tolerance. Curr. Opin. Immunol. 8:233-244.
15. Lewis, L. A., E. Grey, Y. P. Wang, B. A. Roe, and D. W. Dyer. 1997. Molecular characterization of hpuAB, the haemoglobin-haptoglobin-utilization operon of Neisseria meningitidis. Mol. Microbiol. 23:737-749.
16. Makela, P. H., J. Eskola, H. Kayhty, and A. K. Takala. 1995. Vaccines against Haemophilus influenzae type b, p. 42-92. In D. A. A. Ala'Aldeen and C. E. Hormaeche (ed.), Molecular and clinical aspects of bacterial vaccine development. John Wiley and Sons Ltd., Chichester, United Kingdom.
17. Meningococcal genomic sequence database. [Online.] Sanger Centre. http:// www.sanger.ac.uk/Projects/N_meningitidis. [15 November 1998, last date accessed.]
18. Naess, L. M., F. Oftung, A. Aase, L. M. Wetzler, R. Sandin, and T. E. Michaelsen. 1998. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine. Infect. Immun. 66:959-965.
19. Neisseria gonorrhoeae genome sequences. [Online.] University of Oklahoma. http://dna1.chem.ou.edu/gono/html. [15 November 1998, last date accessed.]
20. Palmer, H. M., N. B. L. Powell, D. A. A. Ala'Aldeen, J. Wilton, and S. P. Borriello. 1993. Neisseria meningitidis transferrin binding protein 1 expressed in Escherichia coli is surface exposed and binds human transferrin. FEMS Microbiol. Lett. 110:139-146.
21. Pettersson, A., T. Prinz, A. Umar, J. Bienzen, and J. Tommassen. 1998. Molecular characterization of LbpB, the second lactoferrin-binding protein of Neisseria meningitidis. Mol. Microbiol. 27:559-610.
22. Rijkers, G. T., E. A. M. Sanders, M. A. Breukels, and B. J. M. Zegers. 1996. Responsiveness of infants to capsular polysaccharides: implications for vaccine development. Rev. Med. Microbiol. 7:3-12.
23. Schryvers, A. B., and G. C. Gonzalez. 1989. Comparison of the abilities of different protein sources of iron to enhance Neisseria meningitidis infection in mice. Infect. Immun. 57:2425-2429.
24. Sierra, G. V. G., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-210.
25. + Escherichia coli. Infect. Immun. 61:2908-2911.
26. Thomson, S. A., L. I. Wang, A. West, and P. F. Sparling. 1993. Neisseria meningitidis produces iron-regulated proteins related to the RTX family of exoproteins. J. Bacteriol. 175:811-818.
27. Thornalley, P. J. 1996. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification: a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 27:565-573.
28. Wiertz, E. J. H. J., A. Delvig, E. M. L. M. Donors, H. F. Brugghe, L. A. M. Unen, A. A. M. Termijtelen, M. Achtman, P. Hoogerhout, and J. T. Poolman. 1996. T-cell response to outer membrane proteins of Neisseria meningitidis: comparative study of Opa, Opc, and PorA proteins, class 1 outer membrane proteins. Infect. Immun. 64:298-304.
29. Wiertz, E. J. H. J., J. A. M. Van Gaans-Van den Brink, G. M. T. H. Schreuder, A. A. M. Termijtelen, P. Hoogerhout, and J. T. Poolman. 1991. T cell recognition of Neisseria meningitidis class 1 outer membrane proteins. Identification of T cell epitopes with selected synthetic peptides and determination of HLA restriction elements. J. Immunol. 147:2012-2018.
30. Zollinger, W. D., J. Boslego, E. Moran, J. Garcia, C. Cruz, S. Ruiz, B. Brandt, M. Martinez, J. Arthur, P. Underwood, W. Hankins, J. Mays, J. Gilly, and The Chilean National Committee for Meningococcal Disease. 1991. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. NIPH Ann. 14:211-212.
31. Zollinger, W. D., R. E. Mandrell, J. M. Griffiss, P. Atieri, and S. Berman. 1979. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J. Clin. Invest. 63:836-848.